Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC

This study is comparing two treatment approaches for people with metastatic colorectal cancer (bowel cancer that has spread) who have already tried at least two prior lines of chemotherapy. It compares the combination of regorafenib plus TAS-102 (two chemotherapy-type drugs) against regorafenib alone, to see if the combination is more effective. Both drugs work differently to help stop cancer growth and are already used as later-line options individually. **You may be eligible if...** - You have confirmed metastatic colorectal cancer that has progressed after at least one prior line of standard chemotherapy (including fluoropyrimidine, oxaliplatin, irinotecan, and bevacizumab) - You are physically well enough to carry out some daily activities (ECOG 0–2) - You have at least one measurable tumor on imaging - Your life expectancy is at least 12 weeks - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - Your cancer has not been previously treated with standard first or second-line chemotherapy - You have severe organ problems that would prevent safe use of these drugs - You are pregnant or breastfeeding - You are currently enrolled in another clinical trial with conflicting treatments Talk to your doctor to see if this trial is right for you.